AngioSoma, Inc. Stock Price - SOAN

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Small Cap Pro
Monthly Subscription
for only
$49.05
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
AngioSoma, Inc. SOAN Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.004 40.40% 0.0139 0.0165 0.0117 0.016 0.0099 16:30:19
Bid Price Ask Price Spread Spread % News
0.0124 0.0168 0.0044 26.19% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
128 4,628,782 $ 0.014345 $ 66,400 4,208,156 0.002 - 0.0565
Last Trade Time Type Quantity Stock Price Currency
15:59:45 47,500 $ 0.0139 USD

AngioSoma, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.00M 143.90M $ -816.74k - - 12.49M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
33.74k $ - 0.00% - -

more financials information »

AngioSoma, Inc. News

Loading Messages....

Latest SOAN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SOAN Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.00250.02090.00210.014821M0.0114456.00%
1 Month0.0035950.02090.0020.010010M0.010305286.65%
3 Months0.00840.02090.0020.00864M0.005565.48%
6 Months0.01880.0220.0020.00923M-0.0049-26.06%
1 Year0.0137550.05650.0020.01322M0.0001451.05%
3 Years0.080950.520.0020.0187851k-0.06705-82.83%
5 Years0.512.60.0020.0222615k-0.4961-97.27%

AngioSoma, Inc. Description

AngioSoma, Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). The Company is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.